Ginkgo Bioworks Hldgs Inc (DNA)
13.55 +1.23 (+9.98%) 02/13/25 [NYSE]
13.41 x 100 13.72 x 100
Realtime by (Cboe BZX)
13.41 x 100 13.72 x 100
Realtime 13.50 -0.05 (-0.37%) 19:38 ET
for Thu, Feb 13th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 944,073 | 1,315,792 | 1,550,004 | 380,801 | 0 |
Receivables | 17,899 | 82,465 | 136,142 | 21,906 | 0 |
Inventories | N/A | N/A | 3,362 | 2,736 | 0 |
TOTAL | $1,001,749 | $1,450,079 | $1,723,045 | $426,542 | $0 |
Non-Current Assets | |||||
PPE Net | 188,193 | 314,773 | 145,770 | 121,435 | 0 |
Investments And Advances | 78,565 | 113,731 | 115,231 | 103,124 | 0 |
Intangibles | 131,979 | 171,251 | 42,954 | 5,151 | 0 |
Other Non-Current Assets | 264,856 | 489,487 | 43,990 | 18,901 | 0 |
TOTAL | $663,593 | $1,089,242 | $347,945 | $248,611 | $N/A |
Total Assets | $1,665,342 | $2,539,321 | $2,070,990 | $675,153 | $0 |
Liabilities | |||||
Current Liabilities | |||||
Accounts payable and accrued liabilities | 9,323 | 10,451 | 8,189 | 13,893 | 0 |
Accrued Expenses | 110,051 | 114,694 | 93,332 | 30,505 | 0 |
TOTAL | $163,860 | $172,962 | $134,761 | $73,221 | $0 |
Non-Current Liabilities | |||||
Deferred Revenues | 44,486 | 47,817 | 33,240 | 28,823 | N/A |
aiOther Non-Current Liabilities | 246,268 | 456,758 | 178,425 | 3,146 | 530 |
TOTAL | $404,330 | $630,082 | $368,850 | $131,880 | $N/A |
Total Liabilities | $568,190 | $803,044 | $503,611 | $205,101 | $0 |
Shareholders' Equity | |||||
Shares Outstanding, K | 53,810 | 48,815 | 36,790 | N/A | N/A |
Common Shares | 199 | 190 | 161 | 129 | 0 |
Retained earnings | -5,290,528 | -4,397,659 | -2,297,925 | -467,878 | 0 |
Other shareholders' equity | 1,484 | -2,632 | 60,299 | 8,676 | 0 |
TOTAL | $1,097,152 | $1,736,277 | $1,567,379 | $470,052 | $0 |
Total Liabilities And Equity | $1,665,342 | $2,539,321 | $2,070,990 | $675,153 | $0 |